Company
ORCA Therapeutics
- Biotech
- Locations:
- Amsterdam, Netherlands · 's-Hertogenbosch, Netherlands
Description
ORCA Therapeutics develops oncolytic virus immunotherapies for prostate cancer, producing lead candidate ORCA-010 for treatment‑naive patients and related oncolytic replication competent agent technologies for clinical oncology.
ORCA Therapeutics is located in the Netherlands ecosystem.
Related
TILT BiotherapeuticsTILT Biotherapeutics develops oncolytic viral immunotherapies and engineered viral payloads to modify tumor microenvironments and enhance…
Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
OncolinesOncolines provides precision medicine services in oncology and cancer immunotherapy, offering cell‑based assays, profiling platforms,…
GlycanosticsGlycanostics develops non-invasive liquid biopsy cancer diagnostics, building antibody-coated magnetic particle tests that detect glycan…
HAL AllergyHAL Allergy develops, manufactures, and distributes allergen immunotherapies, including subcutaneous and sublingual products, and produces…
Phlox TherapeuticsPhlox Therapeutics develops precision RNA-based therapies to treat rare genetic cardiomyopathies, creating therapeutic candidates and…
Advantis Medical ImagingAdvantis Medical Imaging provides AI-driven, automated MRI imaging software for analysis of brain and prostate exams, delivering web-based…
BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…